Biodexa Pharmaceuticals Financials - Benzinga

Biodexa Pharmaceuticals PLC

BDRXNASDAQ

Trade with Public

Trade with Public

$1.00

-0.33-24.8%

마지막 업데이트: Sep 16, 12:57 PM

PRO

변동 이유?:Biodexa Pharmaceuticals shares are trading higher after the company announc...

실적: H1 2026 실적이 금 9월 11th에 시장 마감 후 발표되었습니다.

개요 뉴스 실적 전망 이벤트 목표가재무심리 비교 주식 보고서

Biodexa Pharmaceuticals Financials

Biodexa Pharmaceuticals (BDRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Biodexa Pharmaceuticals Expects Initiation Of Phase 3 Registrational Study Of eRapa In FAP, Initiation Of IIT Of Tolimidone In T1D At University Of Alberta As 2025 Clinical Milestones

Benzinga Newsdesk

PRO
Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY

For the year six month period ended June 30 Note2024unaudited£'0002023unaudited£'000Revenue -298Research and development costs (2,189)(2,251)Administrative costs (2,034)(2,291)Loss from

Benzinga Newsdesk

Gold Rises Sharply; Methode Electronics Shares Spike Higher

Avi Kapoor

Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results

Avi Kapoor

Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings

Avi Kapoor

US Stocks Mixed; Target Posts Downbeat Earnings

Avi Kapoor

© 2026 Benzinga | All Rights Reserved